Sfoglia per Autore
Linking tumor immune infiltration to enhanced longevity in recurrence-free breast cancer
2025-01-01 Angelats, L.; Paré, L.; Rubio-Perez, C.; Sanfeliu, E.; González, A.; Seguí, E.; Villacampa, G.; Marín-Aguilera, M.; Pernas, S.; Conte, B.; Albarrán-Fernández, V.; Martínez-Sáez, O.; Aguirre, Á.; Galván, P.; Fernandez-Martinez, A.; Cobo, S.; Rey, M.; Martínez-Romero, A.; Walbaum, B.; Schettini, F.; Vidal, M.; Buckingham, W.; Muñoz, M.; Adamo, B.; Agrawal, Y.; Guedan, S.; Pascual, T.; Agudo, J.; Grzelak, M.; Borcherding, N.; Heyn, H.; Vivancos, A.; Parker, J. S.; Villagrasa, P.; Perou, C. M.; Prat, A.; Brasó-Maristany, F.
Efficacy of adjuvant chemotherapy schedules for breast cancer according to body mass index: results from the phase III GIM2 trial
2024-01-01 Poggio, F.; Blondeaux, E.; Tagliamento, M.; Perachino, M.; Nardin, S.; Conte, B.; Giuliano, M.; Arpino, G.; De Laurentiis, M.; Gravina, A.; Bisagni, G.; Rimanti, A.; Turletti, A.; Nisticò, C.; Magnolfi, E.; Gasparro, S.; Fabi, A.; Garrone, O.; Alicicco, M. G.; Urracci, Y.; Poletti, P.; Correale, P.; Molinelli, C.; Fozza, A.; Puglisi, F.; Colantuoni, G.; Fregatti, P.; Boni, L.; Lambertini, M.; Del Mastro, L.
A 14-gene B-cell immune signature in early-stage triple-negative breast cancer (TNBC): a pooled analysis of seven studies
2024-01-01 Conte, B; Brasó-Maristany, F; Hernández, Ar; Pascual, T; Villacampa, G; Schettini, F; Losada, Mjv; Seguí, E; Angelats, L; Garcia-Fructuoso, I; Gómez-Bravo, R; Lorman-Carbó, N; Paré, L; Marín-Aguilera, M; Martínez-Sáez, O; Adamo, B; Sanfeliu, E; Fratini, B; Falato, C; Chic, N; Vivancos, A; Villagrasa, P; Staaf, J; Parker, Js; Perou, Cm; Prat, A
TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy
2024-01-01 Martin, M.; Stecklein, S. R.; Gluz, O.; Villacampa, G.; Monte-Millan, M.; Nitz, U.; Cobo, S.; Christgen, M.; Braso-Maristany, F.; Alvarez, E. L.; Echavarria, I.; Conte, B.; Kuemmel, S.; Bueno-Muino, C.; Jerez, Y.; Kates, R.; Cebollero, M.; Kolberg-Liedtke, C.; Bueno, O.; Garcia-Saenz, J. A.; Moreno, F.; Grischke, E. -M.; Forstbauer, H.; Braun, M.; Warm, M.; Hackmann, J.; Uleer, C.; Aktas, B.; Schumacher, C.; Wuerstleins, R.; Graeser, M.; Zu Eulenburg, C.; Kreipe, H. H.; Gomez, H.; Massarrah, T.; Herrero, B.; Pare, L.; Bohn, U.; Lopez-Tarruella, S.; Vivancos, A.; Sanfeliu, E.; Parker, J. S.; Perou, C. M.; Villagrasa, P.; Prat, A.; Sharma, P.; Harbeck, N.
Neoadjuvant endocrine therapy for luminal breast tumors: State of the art, challenges and future perspectives
2023-01-01 Sirico, M; Virga, A; Conte, B; Urbini, M; Ulivi, P; Gianni, C; Merloni, F; Palleschi, M; Gasperoni, M; Curcio, A; Saha, D; Buono, G; Muñoz, M; DE GIORGI, U; Schettini, F.
Prognostic value of intrinsic subtypes in hormone-receptor-positive metastatic breast cancer: systematic review and meta-analysis
2023-01-01 Schettini, F; MARTÍNEZ-SÁEZ, O; Falato, C; DE SANTO, I; Conte, B; GARCIA-FRUCTUOSO, I; GOMEZ-BRAVO, R; Segúí, E; Chic, N; BRASÓ-MARISTANY, F; Paré, L; Vidal, M; Adamo, B; Muñoz, M; Pascual, T; Ciruelos, E; Perou, Cm; Carey, La; Prat, A
Anthracycline, taxane, and trastuzumab-based neoadjuvant chemotherapy in HER2-positive early breast cancer: phase II trial
2023-01-01 Conte, B; Montemurro, F; Levaggi, A; Blondeaux, E; Molinelli, C; Cardinali, B; Poggio, F; Buzzatti, G; Bighin, C; Lambertini, M; DEL MASTRO, L
SNPs of aromatase predict long-term survival and aromatase inhibitor toxicity in patients with early breast cancer: a biomarker analysis of the GIM4 and GIM5 trials
2023-01-01 Conte, Benedetta; Boni, Luca; Bisagni, Giancarlo; Durando, Antonio; Sanna, Giovanni; Gori, Stefania; Garrone, Ornella; Tamberi, Stefano; De Placido, Sabino; Schettini, Francesco; Pazzola, Antonio; Ponzone, Riccardo; Montemurro, Filippo; Lunardi, Gianluigi; Notaro, Rosario; De Angioletti, Maria; Turletti, Anna; Mansutti, Mauro; Puglisi, Fabio; Frassoldati, Antonio; Porpiglia, Mauro; Fabi, Alessandra; Generali, Daniele; Scognamiglio, Giovanni; Rossi, Maura; Brasó Maristany, Fara; Prat, Aleix; Cardinali, Barbara; Piccioli, Patrizia; Serra, Martina; Lastraioli, Sonia; Bighin, Claudia; Poggio, Francesca; Lambertini, Matteo; Del Mastro, Lucia
HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1
2023-01-01 BRASÓ-MARISTANY, F; Griguolo, G; Chic, N; Pascual, T; Paré, L; Maues, J; Galván, P; Dieci, Mv; Miglietta, F; Giarratano, T; MARTÍNEZ-SÁEZ, O; MARÍN-AGUILERA, M; Schettini, F; Conte, B; Angelats, L; Vidal, M; Adamo, B; Muñoz, M; Sanfeliu, E; González, B; Vivancos, A; Villagrasa, P; Parker, Js; Perou, Cm; Conte, P; Prat, A; Guarneri, V
Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer
2022-01-01 Prat, A; Guarneri, V; Pascual, T; BRASÓ-MARISTANY, F; Sanfeliu, E; Paré, L; Schettini, F; Martínez, D; Jares, P; Griguolo, G; Dieci, Mv; Cortés, J; LLOMBART-CUSSAC, A; Conte, B; MARÍN-AGUILERA, M; Chic, N; PUIG-BUTILLÉ, Ja; Martínez, A; Galván, P; Tsai, Yh; GONZÁLEZ-FARRÉ, B; Mira, A; Vivancos, A; Villagrasa, P; Parker, Js; Conte, P; Perou, Cm
Intrinsic subtypes and therapeutic decision-making in hormone receptor-positive/HER2-negative metastatic breast cancer with visceral crisis: A case report.
2022-01-01 Schettini, F; Segúí, E; Conte, B; Sanfeliu, E; GONZÁLEZ-FARRE, B; Jares, P; VIDAL-SICART, S; Ganau, S; Cebrecos, I; BRASÓ-MARISTANY, F; Muñoz, M; Prat, A; Vidal, M
De novo Metastatic Breast Cancer Arising in Young Women: Review of the Current Evidence
2022-01-01 Conte, B.; Soldato, D.; Razeti, M. G.; Fregatti, P.; de Azambuja, E.; Schettini, F.; Prat, A.; Del Mastro, L.; Lambertini, M.
Adding a platinum agent to neoadjuvant chemotherapy for triple-negative breast cancer: the end of the debate
2022-01-01 Poggio, F; Tagliamento, M; Ceppi, M; Bruzzone, M; Conte, B; Fregatti, P; Punie, K; DE AZAMBUJA, E; DEL MASTRO, L; Lambertini, M
Breast Cancer Surgery in the COVID-19 Pandemic: Validation of a Preventive Program for Patients and Health Care Workers
2021-01-01 Fregatti, P; Gipponi, M; Giacchino, M; Sparavigna, M; Diaz, R; Fioravanti, E; Cornacchia, C; Conte, B; Lambertini, M; Zoppoli, G; Murelli, F; Toni, Ml; Calabro, Mt; Orsino, L; Friedman, D
Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis
2021-01-01 Schettini, F; Giuliano, M; Giudici, F; Conte, B; DE PLACIDO, P; Venturini, S; Rognoni, C; DI LEO, A; Locci, M; Jerusalem, G; DEL MASTRO, L; Puglisi, F; Conte, P; DE LAURENTIIS, M; Pusztai, L; Rimawi, Mf; Schiff, R; Arpino, G; DE PLACIDO, S; Prat, A; Generali, D
Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor-Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2-Based Therapy
2021-01-01 Pascual, T; FERNANDEZ-MARTINEZ, A; Tanioka, M; Dieci, Mv; Pernas, S; Gavila, J; Guarnieri, V; Cortes, J; Villagrasa, P; Chic, N; Vidal, M; Adamo, B; Muñoz, M; Griguolo, G; Llombart, A; Conte, P; Oliveira, M; Conte, B; Paré, L; Galvan, P; Carey, La; Perou, Cm; Prat, A
T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study
2021-01-01 Conte, B; Schettini, F; Buono, G; DE PLACIDO, P; Parola, S; Griguolo, G; Fabi, A; Bighin, C; Riccardi, F; Cianniello, D; DE LAURENTIIS, M; Puglisi, F; Pelizzari, G; Bonotto, M; Russo, S; Frassoldati, A; Pazzola, A; Montemurro, F; Lambertini, M; Guarneri, V; Cognetti, F; Locci, M; Generalli, D; Conte, P; DE PLACIDO, S; Giuliano, M; Arpino, G; DEL MASTRO, L
Circulating tumor DNA dynamics in advanced breast cancer treated with CDK4/6 inhibition and endocrine therapy
2021-01-01 MARTÍNEZ-SÁEZ, O; Pascual, T; BRASÓ-MARISTANY, F; Chic, N; GONZÁLEZ-FARRÉ, B; Sanfeliu, E; Rodríguez, A; Martínez, D; Galván, P; Rodríguez, Ab; Schettini, F; Conte, B; Vidal, M; Adamo, B; Martínez, A; Muñoz, M; Moreno, R; Villagrasa, P; Salvador, F; Ciruelos, Em; Faull, I; Odegaard, Ji; Prat, A
Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer
2021-01-01 Schettini, F; Chic, N; BRASÓ-MARISTANY, F; Paré, L; Pascual, T; Conte, B; MARTÍNEZ-SÁEZ, O; Adamo, B; Vidal, M; Barnadas, E; FERNÁNDEZ-MARTÍNEZ, A; GONZÁLEZ-FARRÉ, B; Sanfeliu, E; Cejalvo, Jm; Perrone, G; Sabarese, G; Zalfa, F; Peg, V; Fasani, R; Villagrasa, P; Gavilá, J; Barrios, Ch; Lluch, A; Martín, M; Locci, M; DE PLACIDO, S; Prat, A
Italian survey on managing immune checkpoint inhibitors in oncology during COVID-19 outbreak
2020-01-01 Tagliamento, M; Spagnolo, F; Poggio, F; Soldato, D; Conte, B; Ruelle, T; Barisione, E; DE MARIA, A; DEL MASTRO, L; DI MAIO, M; Lambertini, M
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Linking tumor immune infiltration to enhanced longevity in recurrence-free breast cancer | 1-gen-2025 | Angelats, L.; Paré, L.; Rubio-Perez, C.; Sanfeliu, E.; González, A.; Seguí, E.; Villacampa, G.; Marín-Aguilera, M.; Pernas, S.; Conte, B.; Albarrán-Fernández, V.; Martínez-Sáez, O.; Aguirre, Á.; Galván, P.; Fernandez-Martinez, A.; Cobo, S.; Rey, M.; Martínez-Romero, A.; Walbaum, B.; Schettini, F.; Vidal, M.; Buckingham, W.; Muñoz, M.; Adamo, B.; Agrawal, Y.; Guedan, S.; Pascual, T.; Agudo, J.; Grzelak, M.; Borcherding, N.; Heyn, H.; Vivancos, A.; Parker, J. S.; Villagrasa, P.; Perou, C. M.; Prat, A.; Brasó-Maristany, F. | |
| Efficacy of adjuvant chemotherapy schedules for breast cancer according to body mass index: results from the phase III GIM2 trial | 1-gen-2024 | Poggio, F.; Blondeaux, E.; Tagliamento, M.; Perachino, M.; Nardin, S.; Conte, B.; Giuliano, M.; Arpino, G.; De Laurentiis, M.; Gravina, A.; Bisagni, G.; Rimanti, A.; Turletti, A.; Nisticò, C.; Magnolfi, E.; Gasparro, S.; Fabi, A.; Garrone, O.; Alicicco, M. G.; Urracci, Y.; Poletti, P.; Correale, P.; Molinelli, C.; Fozza, A.; Puglisi, F.; Colantuoni, G.; Fregatti, P.; Boni, L.; Lambertini, M.; Del Mastro, L. | |
| A 14-gene B-cell immune signature in early-stage triple-negative breast cancer (TNBC): a pooled analysis of seven studies | 1-gen-2024 | Conte, B; Brasó-Maristany, F; Hernández, Ar; Pascual, T; Villacampa, G; Schettini, F; Losada, Mjv; Seguí, E; Angelats, L; Garcia-Fructuoso, I; Gómez-Bravo, R; Lorman-Carbó, N; Paré, L; Marín-Aguilera, M; Martínez-Sáez, O; Adamo, B; Sanfeliu, E; Fratini, B; Falato, C; Chic, N; Vivancos, A; Villagrasa, P; Staaf, J; Parker, Js; Perou, Cm; Prat, A | |
| TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy | 1-gen-2024 | Martin, M.; Stecklein, S. R.; Gluz, O.; Villacampa, G.; Monte-Millan, M.; Nitz, U.; Cobo, S.; Christgen, M.; Braso-Maristany, F.; Alvarez, E. L.; Echavarria, I.; Conte, B.; Kuemmel, S.; Bueno-Muino, C.; Jerez, Y.; Kates, R.; Cebollero, M.; Kolberg-Liedtke, C.; Bueno, O.; Garcia-Saenz, J. A.; Moreno, F.; Grischke, E. -M.; Forstbauer, H.; Braun, M.; Warm, M.; Hackmann, J.; Uleer, C.; Aktas, B.; Schumacher, C.; Wuerstleins, R.; Graeser, M.; Zu Eulenburg, C.; Kreipe, H. H.; Gomez, H.; Massarrah, T.; Herrero, B.; Pare, L.; Bohn, U.; Lopez-Tarruella, S.; Vivancos, A.; Sanfeliu, E.; Parker, J. S.; Perou, C. M.; Villagrasa, P.; Prat, A.; Sharma, P.; Harbeck, N. | |
| Neoadjuvant endocrine therapy for luminal breast tumors: State of the art, challenges and future perspectives | 1-gen-2023 | Sirico, M; Virga, A; Conte, B; Urbini, M; Ulivi, P; Gianni, C; Merloni, F; Palleschi, M; Gasperoni, M; Curcio, A; Saha, D; Buono, G; Muñoz, M; DE GIORGI, U; Schettini, F. | |
| Prognostic value of intrinsic subtypes in hormone-receptor-positive metastatic breast cancer: systematic review and meta-analysis | 1-gen-2023 | Schettini, F; MARTÍNEZ-SÁEZ, O; Falato, C; DE SANTO, I; Conte, B; GARCIA-FRUCTUOSO, I; GOMEZ-BRAVO, R; Segúí, E; Chic, N; BRASÓ-MARISTANY, F; Paré, L; Vidal, M; Adamo, B; Muñoz, M; Pascual, T; Ciruelos, E; Perou, Cm; Carey, La; Prat, A | |
| Anthracycline, taxane, and trastuzumab-based neoadjuvant chemotherapy in HER2-positive early breast cancer: phase II trial | 1-gen-2023 | Conte, B; Montemurro, F; Levaggi, A; Blondeaux, E; Molinelli, C; Cardinali, B; Poggio, F; Buzzatti, G; Bighin, C; Lambertini, M; DEL MASTRO, L | |
| SNPs of aromatase predict long-term survival and aromatase inhibitor toxicity in patients with early breast cancer: a biomarker analysis of the GIM4 and GIM5 trials | 1-gen-2023 | Conte, Benedetta; Boni, Luca; Bisagni, Giancarlo; Durando, Antonio; Sanna, Giovanni; Gori, Stefania; Garrone, Ornella; Tamberi, Stefano; De Placido, Sabino; Schettini, Francesco; Pazzola, Antonio; Ponzone, Riccardo; Montemurro, Filippo; Lunardi, Gianluigi; Notaro, Rosario; De Angioletti, Maria; Turletti, Anna; Mansutti, Mauro; Puglisi, Fabio; Frassoldati, Antonio; Porpiglia, Mauro; Fabi, Alessandra; Generali, Daniele; Scognamiglio, Giovanni; Rossi, Maura; Brasó Maristany, Fara; Prat, Aleix; Cardinali, Barbara; Piccioli, Patrizia; Serra, Martina; Lastraioli, Sonia; Bighin, Claudia; Poggio, Francesca; Lambertini, Matteo; Del Mastro, Lucia | |
| HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1 | 1-gen-2023 | BRASÓ-MARISTANY, F; Griguolo, G; Chic, N; Pascual, T; Paré, L; Maues, J; Galván, P; Dieci, Mv; Miglietta, F; Giarratano, T; MARTÍNEZ-SÁEZ, O; MARÍN-AGUILERA, M; Schettini, F; Conte, B; Angelats, L; Vidal, M; Adamo, B; Muñoz, M; Sanfeliu, E; González, B; Vivancos, A; Villagrasa, P; Parker, Js; Perou, Cm; Conte, P; Prat, A; Guarneri, V | |
| Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer | 1-gen-2022 | Prat, A; Guarneri, V; Pascual, T; BRASÓ-MARISTANY, F; Sanfeliu, E; Paré, L; Schettini, F; Martínez, D; Jares, P; Griguolo, G; Dieci, Mv; Cortés, J; LLOMBART-CUSSAC, A; Conte, B; MARÍN-AGUILERA, M; Chic, N; PUIG-BUTILLÉ, Ja; Martínez, A; Galván, P; Tsai, Yh; GONZÁLEZ-FARRÉ, B; Mira, A; Vivancos, A; Villagrasa, P; Parker, Js; Conte, P; Perou, Cm | |
| Intrinsic subtypes and therapeutic decision-making in hormone receptor-positive/HER2-negative metastatic breast cancer with visceral crisis: A case report. | 1-gen-2022 | Schettini, F; Segúí, E; Conte, B; Sanfeliu, E; GONZÁLEZ-FARRE, B; Jares, P; VIDAL-SICART, S; Ganau, S; Cebrecos, I; BRASÓ-MARISTANY, F; Muñoz, M; Prat, A; Vidal, M | |
| De novo Metastatic Breast Cancer Arising in Young Women: Review of the Current Evidence | 1-gen-2022 | Conte, B.; Soldato, D.; Razeti, M. G.; Fregatti, P.; de Azambuja, E.; Schettini, F.; Prat, A.; Del Mastro, L.; Lambertini, M. | |
| Adding a platinum agent to neoadjuvant chemotherapy for triple-negative breast cancer: the end of the debate | 1-gen-2022 | Poggio, F; Tagliamento, M; Ceppi, M; Bruzzone, M; Conte, B; Fregatti, P; Punie, K; DE AZAMBUJA, E; DEL MASTRO, L; Lambertini, M | |
| Breast Cancer Surgery in the COVID-19 Pandemic: Validation of a Preventive Program for Patients and Health Care Workers | 1-gen-2021 | Fregatti, P; Gipponi, M; Giacchino, M; Sparavigna, M; Diaz, R; Fioravanti, E; Cornacchia, C; Conte, B; Lambertini, M; Zoppoli, G; Murelli, F; Toni, Ml; Calabro, Mt; Orsino, L; Friedman, D | |
| Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis | 1-gen-2021 | Schettini, F; Giuliano, M; Giudici, F; Conte, B; DE PLACIDO, P; Venturini, S; Rognoni, C; DI LEO, A; Locci, M; Jerusalem, G; DEL MASTRO, L; Puglisi, F; Conte, P; DE LAURENTIIS, M; Pusztai, L; Rimawi, Mf; Schiff, R; Arpino, G; DE PLACIDO, S; Prat, A; Generali, D | |
| Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor-Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2-Based Therapy | 1-gen-2021 | Pascual, T; FERNANDEZ-MARTINEZ, A; Tanioka, M; Dieci, Mv; Pernas, S; Gavila, J; Guarnieri, V; Cortes, J; Villagrasa, P; Chic, N; Vidal, M; Adamo, B; Muñoz, M; Griguolo, G; Llombart, A; Conte, P; Oliveira, M; Conte, B; Paré, L; Galvan, P; Carey, La; Perou, Cm; Prat, A | |
| T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study | 1-gen-2021 | Conte, B; Schettini, F; Buono, G; DE PLACIDO, P; Parola, S; Griguolo, G; Fabi, A; Bighin, C; Riccardi, F; Cianniello, D; DE LAURENTIIS, M; Puglisi, F; Pelizzari, G; Bonotto, M; Russo, S; Frassoldati, A; Pazzola, A; Montemurro, F; Lambertini, M; Guarneri, V; Cognetti, F; Locci, M; Generalli, D; Conte, P; DE PLACIDO, S; Giuliano, M; Arpino, G; DEL MASTRO, L | |
| Circulating tumor DNA dynamics in advanced breast cancer treated with CDK4/6 inhibition and endocrine therapy | 1-gen-2021 | MARTÍNEZ-SÁEZ, O; Pascual, T; BRASÓ-MARISTANY, F; Chic, N; GONZÁLEZ-FARRÉ, B; Sanfeliu, E; Rodríguez, A; Martínez, D; Galván, P; Rodríguez, Ab; Schettini, F; Conte, B; Vidal, M; Adamo, B; Martínez, A; Muñoz, M; Moreno, R; Villagrasa, P; Salvador, F; Ciruelos, Em; Faull, I; Odegaard, Ji; Prat, A | |
| Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer | 1-gen-2021 | Schettini, F; Chic, N; BRASÓ-MARISTANY, F; Paré, L; Pascual, T; Conte, B; MARTÍNEZ-SÁEZ, O; Adamo, B; Vidal, M; Barnadas, E; FERNÁNDEZ-MARTÍNEZ, A; GONZÁLEZ-FARRÉ, B; Sanfeliu, E; Cejalvo, Jm; Perrone, G; Sabarese, G; Zalfa, F; Peg, V; Fasani, R; Villagrasa, P; Gavilá, J; Barrios, Ch; Lluch, A; Martín, M; Locci, M; DE PLACIDO, S; Prat, A | |
| Italian survey on managing immune checkpoint inhibitors in oncology during COVID-19 outbreak | 1-gen-2020 | Tagliamento, M; Spagnolo, F; Poggio, F; Soldato, D; Conte, B; Ruelle, T; Barisione, E; DE MARIA, A; DEL MASTRO, L; DI MAIO, M; Lambertini, M |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile